References
- Smith J. R., Levinson R. D., Holland G. N., Jabs D. A., Robinson M. R., Whitcup S. M., et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252–7
- Sobrin L., Kim E. C., Christen W., Papadaki T., Letko E., Foster C. S. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007; 125: 895–900
- Sfikakis P. P., Theodossiadis P. G., Katsiari C. G., Kaklamanis P., Markomichelakis N. N. Effect of infliximab on sight‐threatening panuveitis in Behçet's disease. Lancet 2001; 358: 295–6
- Joseph A., Raj D., Dua H. S., Powell P. T., Lanyon P. C., Powell R. J. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003; 110: 1449–53
- Ohno S., Nakamura S., Hori S., Shimakawa M., Kawashima H., Mochizuki M., et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004; 31: 1362–8
- Sfikakis P. P., Kaklamanis P. H., Elezoglou A., Katsilambros N., Theodossiadis P. G., Papaefthimiou S., et al. Infliximab for recurrent, sight‐threatening ocular inflammation in Adamantiades–Behçet disease. Ann Intern Med 2004; 140: 404–6
- Lanthier N., Parc C., Scavennec R., Dhote R., Brezin A. P., Guillevi L. Infliximab in the treatment of posterior uveitis in Behçet's disease. Long‐term follow‐up in four patients. Presse Med 2005; 34: 916–18
- Murphy C. C., Ayliffe W. H., Booth A., Makanjuola D., Andrews P. A., Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004; 111: 352–6
- Nussenblatt R. B., Palestine A. G., Chan C. C., Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92: 467–71
- Tugal‐Tutkun I., Mudun A., Urgancioglu M., Kamali S., Kasapoglu E., Inanc M., et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open‐label trial. Arthritis Rheum 2005; 52: 2478–84
- Markomichelakis N. N., Theodossiadis P. G., Pantelia E., Papaefthimiou S., Theodossiadis G. P., Sfikakis P. P. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004; 138: 648–50
- Lindstedt E. W., Baarsma G. S., Kuijpers R. W., van Hagen P. M. Anti‐TNF‐alpha therapy for sight‐threatening uveitis. Br J Ophthalmol 2005; 89: 533–6
- Niccoli L., Nannini C., Benucci M., Chindamo D., Cassara E., Salvarani C., et al. Long‐term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24‐month follow‐up study. Rheumatology (Oxford) 2007; 46: 1161–4
- Suhler E. B., Smith J. R., Wertheim M. S., Lauer A. K., Kurz D. E., Pickard T. D., et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123: 903–12